| Next 10 |
Stock Information
MENU
GERN
GERN Quote
GERN Short
GERN News
GERN Articles
GERN Message Board
Get GERN Alerts
News, Short Squeeze, Breakout and More Instantly...
RECENT GERN NEWS
-
Pivotal Software (NYSE: PVTL ) +73% with VMware in acquisition talks . More news on: Pivotal Software, Inc., Sintx Technologies, Inc., Bridgeline Digital, Inc. Read more ...
-
Geron (NASDAQ: GERN ) initiated with Overweight rating and $4 (210% upside) price target at Cantor Fitzgerald. Shares up 2% premarket. More news on: Geron Corporation, Blueprint Medicines Corporation, Elanco Animal Health Incorporated, Healthcare stocks news, Stocks on the move...
-
Many of our best shorts come when we can identify large gaps between how bullish investors and management are portraying a situation and what we think the objective facts support. In the case of Overstock.com, we believe the gap between perception and reality is as wide as we have ever seen....
GERN News and Press, Geron Corporation
-
Pivotal Software (NYSE: PVTL ) +73% with VMware in acquisition talks . More news on: Pivotal Software, Inc., Sintx Technologies, Inc., Bridgeline Digital, Inc. Read more ...
-
Geron (NASDAQ: GERN ) initiated with Overweight rating and $4 (210% upside) price target at Cantor Fitzgerald. Shares up 2% premarket. More news on: Geron Corporation, Blueprint Medicines Corporation, Elanco Animal Health Incorporated, Healthcare stocks news, Stocks on the move...
-
Many of our best shorts come when we can identify large gaps between how bullish investors and management are portraying a situation and what we think the objective facts support. In the case of Overstock.com, we believe the gap between perception and reality is as wide as we have ever seen....
-
MENLO PARK, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MD...
-
Following the breakdown of the collaboration with JNJ, Geron ( GERN ) is finally ready to restart imetelstat's development. The Investigational New Drug ("IND") sponsorship transfer is now complete and the phase 3 trial for imetelstat in lower risk myelodysplastic syndrome ("MDS") is going to ...
-
Geron Corp (GERN) Q2 2019 Earnings Conference Call August 01, 2019, 16:30 ET Company Participants Suzanne Messere - Head, IR & Corporate Communications John Scarlett - CEO, President & Chairman Olivia Bloom - EVP, Finance, CFO & Treasurer Aleksandra Rizo - EVP &...
-
Geron (NASDAQ: GERN ): Q2 GAAP EPS of -$0.08 beats by $0.02 . Revenue of $0.1M (-52.4% Y/Y) misses by $0.05M . Press Release More news on: Geron Corporation, Earnings news and commentary, Healthcare stocks news, ,
-
MENLO PARK, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the second quarter ended June 30, 2019, and recent events. The Company ended the second quarter with $162.3 million in cash and marketable securities. During the sec...
-
MENLO PARK, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2019 financial results after the market closes on Thursday, August 1, 2019 via press release, which will be available on the Company’s websit...
-
MENLO PARK, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Sharon McBain as Vice President, Global Regulatory Affairs and Lynn Bodarky as Vice President, Business Development. These appointments further enhance the Company ...
